Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
VIREAD (tenofovir disoproxil fumarate) is an oral nucleotide reverse transcriptase inhibitor approved in 2001 for the treatment of HIV-1 infection and chronic hepatitis B. It works by inhibiting reverse transcriptase, blocking viral replication in infected cells. The drug is a foundational antiretroviral therapy component used in combination regimens.
Product approaching loss of exclusivity with moderate competitive pressure (60/100), signaling transition from growth to defense strategies and potential team restructuring.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate
Worked on VIREAD at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on VIREAD offers limited growth trajectory given the product's LOE-approaching status and low linked job count (0), but provides valuable experience in managing mature, highly competitive therapeutic categories and defensive commercial strategies. Professionals should expect focus on market defense, managed care negotiations, and lifecycle extension rather than launch-phase innovation opportunities.